Tag Archives | HCV

Biotech Bull Market-Trends to Watch #2: ETF Review-FBT XBI

Biotech and Healthcare ETFs Hit An All Time High–Another Rally Coming Today 3/20 M&A: Recent buy-outs of Cubist (CBST) for $9.5B and Pharmacyclics (PCYC) for $21B have raised the valuation bar. The healthcare sector remains strong and biopharmaceuticals are key to sales growth. Breakthroughs in genomics, targeted oncology and HCV drugs are blockbuster growth areas. […]

Continue Reading 0

Rayno Biopharmaceutical Stocks: PCYC Buzz Drive Biotechs Higher… Update-1

2/27 Friday After a big February biotechs turned red today with major ETFs off about 1%. In light of recent M&A talk about Pharmacyclics, Inc. (PCYC) at Market Cap of $16.6B we will look at other top Mid-Cap biopharmaceutical stocks for comparison to our motif below: ALNY, BMRN, INCY, MDVN, PBYI etc. Rayno Mid-Caps Outperform […]

Continue Reading

Rayno Dx and Tools: 2015 Q1 Mid Quarter Update-FMI, CSII, HOLX, ALR

Bullish Trend Continues for Mid-Cap Growth Stocks The Life Science Tools and Clinical Diagnostics sector kept pace with major life science ETF performance. Major  ETFs (FBT,IBB,XBI) are up about 10% YTD and our top performers are up over 10%. We will provide an update of our  Clinical Diagnostics portfolio after all earnings reports are in. […]

Continue Reading

Biotech Stocks Rally With Broad Market-Energy A Loser

Energy Stocks Down-Biotech and Healthcare Stocks Are Leaders NASDAQ Up 1.30%     4787 After a few days in the doldrums biotech stocks rallied across the board escaping the drag of macro news. Healthcare and technology sectors were among the leaders of the day moving in the opposite direction from energy. There have been dual […]

Continue Reading

Biotech Stocks Hit By Profit Taking: Risk Off- GILD News…Update

2/4/15 After the Bell ECB Impasse with Greece Hits Market Near Close…….. NASDAQ 4221 Down 0.19% Oil Plunges 9% to $48.74 on Inventory Rise Biotech Stocks Try To Recover But Get Hit By ECB News At Close ETFs down about 1.6% , XBI Down 1.9%, XLV down 1.24% Gilead (GILD) closes at $98.43 above lows […]

Continue Reading